Casebia Therapeutics Competitors, Revenue and Alternatives
Estimated Revenue & Financials
- Casebia Therapeutics's estimated annual revenue is currently $16.9M per year.
- Casebia Therapeutics's estimated revenue per employee is $155,000
- Casebia Therapeutics has 109 Employees.
- Casebia Therapeutics grew their employee count by 38% last year.
- Casebia Therapeutics currently has 1 job openings.
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|Cell Signaling ...||$89.4M||577||N/A||N/A|
What Is Casebia Therapeutics?
Bayer and CRISPR Therapeutics have entered into an agreement to create Casebia to discover, develop and commercialize new breakthrough therapeutics to cure blood disorders, blindness, and congenital heart disease. CRISPR Therapeutics will contribute its proprietary CRISPR-Cas9 gene-editing technology and intellectual property, while Bayer will make available its protein engineering expertise and relevant disease know-how. It is the first long-term strategic partnership of its kind to make a substantial investment in the development of target delivery systems in an effort to bring systemic in vivo CRISPR-Cas9 gene editing technology applications to patients.keywords:N/A
Number of Employees
Employee Growth %
|Abraham Scaria||Vp, Head Of Ophthalmology||Email Available|
|Adel Nada||Chief Medical Officer|
|Ileen Winick||Senior Vice President, Human Resources|
|Debi Harmon||Senior Director Human Resources|
|Vilmary Torres||Accounting Manager|
|Robin Walker||Senior Vice President, Head Of Legal|
|Bindu Ranganath||Manager Fp&a|
|Joshua Merritt||Director, Manufacturing And Process Development (aav)|
|Christopher Cheng||Director, RNA Technology|
|Andy Scharenberg||Chief Scientific Officer|
Casebia Therapeutics News
... with small startups, including its 2016 Casebia Therapeutics, formed by Bayer and CRISPR Therapeutics, which aims to cure blood disorders ...
Editas and Intellia, like CRISPR Therapeutics, reached 12-month lows .... Casebia was launched in December 2015 when Bayer agreed to pay ...
Thirteen biopharma companies, including Sangamo Therapeutics and ... James Burns, CEO of Casebia Therapeutics, one of the co-signers, ...
Casebia Therapeutics Executive Hires
|2016-11-02||James Burns||President/Chief Executive Officer||Article|
|2017-05-12||Ellen Ridge||SVP Operations||Article|
|2017-05-12||Abraham Scaria||VP Ophthalmology||Article|
|2017-06-29||Robin Walker||VP Head of Legal||Article|
|2017-09-11||Michael Laska||VP CMC Development and Manufacturing||Article|
|2018-05-31||Amy Jennings||Head Its Regulatory Affairs||Article|
|2018-11-01||Adel Nada||Chief Medical Officer||Article|